Dermato®bromas have an increased brownish color due to hyperpigmentation of the overlying skin. To determine paracrine factors involved in the epidermal hyperpigmentation, we have studied the expression of cytokines in lesional and nonlesional dermato®broma skin at the transcriptional and protein levels using reverse transcription polymerase chain reaction and immunohistochemistry, respectively. The number of tyrosinase immuno-positive melanocytes in the pigmented dermato®broma epidermis is signi®cantly increased (2-fold) compared with nonlesional normal epidermis. Reverse transcription polymerase chain reaction analysis of mRNAs encoding stem cell factor and hepatocyte growth factor demonstrated that there is an accentuated expression of stem cell factor and hepatocyte growth factor transcripts in the lesional dermato®-broma dermis compared with the nonlesional dermis, although there is no difference in their expression between the lesional and nonlesional epidermis. In contrast, mRNA transcripts encoding endothelin-1, growth-related oncogene a, and basic ®broblast growth factor are not increased in lesional epidermis or in dermis relative to nonlesional skin. In parallel, immunohistochemical analysis using antibodies to stem cell factor and hepatocyte growth factor reveal a marked immunostaining in growing ®broblastic tumor cells in the dermato®broma lesions with no detectable staining in the nonlesional dermis, but there is no difference in their immunostaining between the lesional and nonlesional epidermis. Interestingly, and consistent with the increased expression of stem cell factor in lesional dermato®-broma dermis, toluidine blue staining in the dermis revealed a 5-fold increase in the number of mast cells, an indication of their longevity or accumulation induced by stem cell factor. These ®ndings suggest an important role of ®broblastic tumor cellderived stem cell factor in the mechanism involved in the hyperpigmentation of the dermato®broma epidermis.
Dermato®bromas have an increased brownish color due to hyperpigmentation of the overlying skin. To determine paracrine factors involved in the epidermal hyperpigmentation, we have studied the expression of cytokines in lesional and nonlesional dermato®broma skin at the transcriptional and protein levels using reverse transcription polymerase chain reaction and immunohistochemistry, respectively. The number of tyrosinase immuno-positive melanocytes in the pigmented dermato®broma epidermis is signi®cantly increased (2-fold) compared with nonlesional normal epidermis. Reverse transcription polymerase chain reaction analysis of mRNAs encoding stem cell factor and hepatocyte growth factor demonstrated that there is an accentuated expression of stem cell factor and hepatocyte growth factor transcripts in the lesional dermato®-broma dermis compared with the nonlesional dermis, although there is no difference in their expression between the lesional and nonlesional epidermis. In contrast, mRNA transcripts encoding endothelin-1, growth-related oncogene a, and basic ®broblast growth factor are not increased in lesional epidermis or in dermis relative to nonlesional skin. In parallel, immunohistochemical analysis using antibodies to stem cell factor and hepatocyte growth factor reveal a marked immunostaining in growing ®broblastic tumor cells in the dermato®broma lesions with no detectable staining in the nonlesional dermis, but there is no difference in their immunostaining between the lesional and nonlesional epidermis. Interestingly, and consistent with the increased expression of stem cell factor in lesional dermato®-broma dermis, toluidine blue staining in the dermis revealed a 5-fold increase in the number of mast cells, an indication of their longevity or accumulation induced by stem cell factor. These ®ndings suggest an important role of ®broblastic tumor cellderived stem cell factor in the mechanism involved in the hyperpigmentation of the dermato®broma epidermis. Key words: cytokines/®broblasts/mast cell/ melanocytes. J Invest Dermatol 117: 627±633, 2001 D ermato®broma (DF) is a benign dermal tumor of ®broblast-like cells (Heenan, 1997) ; it is also known as histiocytoma, benign ®brous histiocytoma, and sclerosing hemangioma. It has been reported that some cases of multiple DF are associated with autoimmune diseases such as systemic lupus erythematosus (Newman and Walter, 1973; Lin, 1986) . In lesional DF skin, there is an abnormal accumulation of proliferating ®broblast-like cells and histiocytes surrounded by mature collagen and by increased capillaries. Of particular interest is the fact that the epidermis overlying the DF tumor is markedly hyperpigmented with a slight acanthosis (Heenan, 1997) , although the mechanism behind the pathogenesis of the epidermal hyperpigmentation remains to be clari®ed. It has been well established that typical epidermal pigmentation is accompanied by an increased number of melanocytes and by an enhanced melanization associated with increases in melanocyte proliferation and expression of tyrosinase, respectively.
In ultraviolet (UV) induced epidermal pigmentation, the paracrine cytokine linkage between keratinocytes and melanocytes within the epidermis is documented to play an essential role in accentuating the proliferation and melanogenesis of melanocytes (Imokawa et al, 1992 (Imokawa et al, , 1995 (Imokawa et al, , 1996a . Those cytokines include endothelins (ET) and granulocyte±macrophage colony stimulating factor (GM-CSF), which are involved in UVB-and UVA-induced epidermal pigmentation. Furthermore, in non-UV associated pigmentary disorders, such as seborrheic keratosis (Teraki et al, 1996) and lentigo senilis (Kadono et al, 2001 ), a similar paracrine cytokine such as ET is an intrinsic melanogenic factor responsible for stimulating proliferation and melanogenesis by melanocytes. It has also been reported that important cytokines in the paracrine linkage between ®broblasts and melanocytes in cutaneous human pigmentation include stem cell factor (SCF) and hepatocyte growth factor (HGF) (Imokawa et al, 1998b) . As SCF and HGF derived from human ®broblasts regulate cutaneous pigmentation, those cytokines might be derived from ®broblastic tumor cells in DF and may be involved in the epidermal hyperpigmentation.
To test this hypothesis, we investigated gene expression and protein levels of ®broblastic tumor cell derived melanogenic factors such as SCF, HGF, basic ®broblast growth factor (bFGF), growth- related oncogene a (GRO-a), and ET-1 in DF using reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry. Here we report that the mechanism of epidermal hyperpigmentation in DF involves SCF and HGF, which are secreted in abundance by the ®broblastic tumor cells and which induce melanogenic stimulation in the adjacent epidermal melanocytes.
MATERIALS AND METHODS
Materials Streptavidin±biotin immunoperoxidase staining systems were obtained from Shandon-Lipshaw (Pennsylvania).
Antibodies Polyclonal antibodies speci®c for human SCF (Yamataka et al, 1998) , ET-1, HGF (Takanami et al, 1996) , bFGF, and GRO-a were purchased from Immuno Biological Laboratories (IBL, Gunma, Japan). The monoclonal antibody to human tyrosinase was obtained from Biochemical Industrial (Tokyo, Japan).
Skin samples Skin biopsy specimens were obtained from DF lesional and perilesional skin (n = 13, four Japanese males and nine Japanese females, mean age 33.7 y). The representative clinical appearance of DF and the skin architecture of these lesions are shown in Fig 1(A) . All DF studied had dark brownish color on the overlying skin. The sites of skin excisions were the abdomen, the extremities, and the buttocks, which are generally sun-protected skin areas, and there were no symptoms of sun exposure when the biopsies were taken. The main portion of each specimen was subjected to routine histopathologic examination. The remaining sample specimens were embedded in Tissue-Tek OCT compound (Miles, Indiana), snap-frozen in liquid nitrogen, and then stored at ±80°C until use.
Immunohistochemistry Cryostat sections (4 mm thick) were airdried, ®xed in cold acetone, washed in 0.01 M phosphate-buffered saline pH 7.2 (PBS+), and then incubated in 3% H 2 O 2 for 5 min at room temperature. After further washing in PBS(+), sections were incubated with the protein blocking agent for 20 min at room temperature. After washing again in PBS(+), the sections were incubated overnight at 4°C in PBS(+) containing antibodies (1:50) to SCF, HGF, bFGF, ET-1, GRO-a, or tyrosinase. After further washing in PBS(+), the sections were incubated for 30 min at room temperature with rabbit IgG antibody. The sections were again washed in PBS(+) and were then incubated for 30 min at room temperature with standard Omnitags streptavidin-peroxidase.
The reaction was developed with aminoethylcarbazole (AEC); the sections were incubated for 10±15 min at room temperature with Omnitags plus/HRP kit consisting of two drops of sodium acetate buffer, two drops of AEC chromogen concentrate, and two drops of 3% H 2 O 2 in distilled water. The sections were then washed in PBS(+) and stained with hematoxylin±eosin.
RT-PCR Biopsy specimens were obtained from the skin as detailed above and the adipose tissue was removed with a surgical knife. The epidermis and the dermis of each specimen was then separated by heating for 3 min at 60°C. The residue of separated tissue was examined after periodic acid±Schiff (PAS) staining to con®rm that the separation took place within the epidermis, leaving no dermal components on the epidermal sheet. Total cellular RNA was then extracted from the epidermis and from the dermis using the acid guanidinium phenol chloroform method with only a single precipitation. The RNA was quanti®ed by measuring the optical density at 260 nm, and about 1 mg of total RNA was obtained from each tissue sample. To synthesize oligo(dT16)-primed cDNA, total RNA was heated to 65°C for 3 min, and then chilled on ice. Reverse transcription was performed in 20 ml reaction mixtures containing 2 ml 10 Q PCR buffer II: 4 ml MgCl 2 (25 mM), 1 ml oligo(dT16) (2.5 mM), 8 ml deoxynucleotides (2.5 mM each), 1 ml RNase inhibitor (1 U per ml), 1 ml Moloney murine leukemia virus reverse transcriptase (2.5 U per ml), and 3 ml RNA -TTCCCACAAAGGCAACAGACCG-3¢  3¢ primer 5¢-GACAGGCCCCGAAGTCTGTCA-3¢  bFGF  243 bp  5¢ primer 5¢-GGAGTGTGTGCTAACCGTTACCTGGCTATG-3¢  3¢ primer 5¢-TCAGCTCTTAGCAGACATTGGAAGAAAAAG-3¢  GRO-a 250 bp 5¢ primer 5¢-GGATCCAAGCAAATGGCCAATGAG-3¢ 3¢ primer 5¢-TGTTCTAAGCCAGAAACACTG-3¢ SCF 351 bp 5¢ primer 5¢-GATGTTTTGCCAAGTCATTGTTGG-3¢ 3¢ primer 5¢-ACTGACTCTGGAATCTTTCTCAGG-3¢ HGF 396 bp 5¢ primer 5¢-GTTATCGTGGGAATGGCAA-3¢ 3¢ primer 5¢-ATGATCCTCCGCAGATATG-3¢ GAPDH 516 bp 5¢ primer 5¢-GAAGGTGAAGGTCGGAGTCAACG-3¢ 3¢ primer 5¢-AGTCCTTCCACGATACCAAAGTTG-3¢
(100 ng in DEPC-treated water). Reaction mixtures were incubated at 42°C for 60 min and at 52°C for 30 min, and then heated to 99°C for 5 min to inactivate the reverse transcriptase. For PCR ampli®cation, 3 ml of each cDNA reaction mixture was added to an 80 ml PCR mixture containing 4 ml MgCl 2 (2 mM), 8 ml 10 Q PCR buffer II, 5 ml 3¢ and 5¢ primers (10 mM each), and 1 ml Taq polymerase (Cetus). Reaction mixtures were ampli®ed using a Perkin-Elmer/Cetus thermal cycler. The PCR cycle conditions were: melting for 1 min at 95°C, annealing for 1 min at 60°C, and extension for 2 min at 72°C. Reaction products (1.5 ml) were resolved on 1.5% agarose gels and were visualized by ethidium bromide staining. The sequences of the 3¢ and 5¢ primer pairs used in this study are shown in Table I . As negative controls, we conducted PCR without reverse transcriptase and con®rmed that there was no ampli®cation of the transcripts. To quantitate the expression of the transcripts, the intensities of PCR bands were measured by densitometry and are expressed as relative intensities to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Statistics The levels of signi®cance of differences were calculated by the Student t test.
RESULTS

Melanocytes proliferate in DF epidermis
Immunostaining of epidermal melanocytes with a tyrosinase antibody (Fig 1B) reveals that there is an increase in tyrosinase-positive melanocytes in lesional DF epidermis compared with nonlesional epidermis. Quantitation of tyrosinase-positive melanocytes per millimeter length of the horizontal interface between the epidermis and dermis, or per 100 basal cells, demonstrates that the number of melanocytes signi®cantly increases in the lesional DF epidermis compared with the nonlesional epidermis (Fig 1C) .
RT-PCR analysis of melanogenic cytokines We measured the gene expression of melanogenic cytokines (SCF, HGF, bFGF, GRO-a, and ET-1) in nonlesional and in lesional DF epidermis and dermis. In the epidermis, three (Nos. 1, 2, and 5) out of six cases had a slight expression of SCF transcript, but the levels of distinct expression found in two (Nos. 1 and 2) of the other three cases did not differ between the nonlesional and the lesional DF epidermis (Fig 2A) . In contrast, the gene expression of SCF in the lesional dermis was de®nitely increased (average 1.68-fold, n = 6) compared with the nonlesional controls in ®ve out of the six cases (Fig 2A) . Using RT-PCR analysis, there was no expression of HGF mRNA either in the nonlesional or in the lesional DF epidermis under our experimental conditions, but in the dermis HGF gene expression was markedly increased (average 2.27-fold, n = 6) relative to the nonlesional dermis in all six cases (Fig 2B) .
On the other hand, the results of RT-PCR analysis for bFGF, GRO-a, and ET-1 differed from those for SCF and HGF. There was no difference in bFGF expression in the epidermis or dermis (average 0.84-fold, n = 6) in lesional and nonlesional skin (Fig 2C) . GRO-a was also similar in lesional and nonlesional epidermis and dermis (average 0.79-fold, n = 6), except for possibly slightly decreased expression in the epidermis in some lesions (Fig 2D) . The results of RT-PCR analysis of ET-1 mRNA showed similar levels in the nonlesional and the lesional DF epidermis and dermis (average 0.95-fold, n = 6) ( Fig 2E) .
Immunohistochemistry Keratinocytes stained positively for SCF, HGF, bFGF, GRO-a, and ET-1 in the nonlesional and the lesional DF epidermis (Fig 3) . In addition, dermal blood vessels, several ducts, glands, and hair follicles were also stained. Although positive staining for these ®ve cytokines was con®ned to ®broblastic tumor cells in the lesional dermis, there was negative or poor staining for SCF or HGF in normal ®broblasts in the nonlesional dermis (Fig 3A, B) . It is clear that levels of positive staining for bFGF, GRO-a, and ET-1 in the nonlesional DF ®broblasts are similar to those found in individual cells of the lesional tumor (Fig 3C±E) . Consistent with the elevated level of SCF in the dermis, there was an increased number of mast cells surrounding the tumor measured using toluidine blue staining (Fig 4A) . In the DF tumor lesion, there was about a 5-fold increase in the number of mast cells compared with those in the normal dermis (Fig 4B) .
DISCUSSION
In epidermal pigmentary disorders, the paracrine network of cytokines plays an essential role in stimulating epidermal melanocytes following their secretion by nonmelanocytic cells in the skin (Teraki et al, 1996; Imokawa et al, 1997; Kadono et al, 2001 ). In UVB-induced pigmentation, ET-1 and membrane-bound SCF have been associated as keratinocyte-derived cytokines that stimulate melanogenesis in epidermal melanocytes (Imokawa et al, 1992 (Imokawa et al, , 1995 Hachiya et al, 2001 ). In contrast, in UVA-induced pigmentation, GM-CSF has been identi®ed as a keratinocyte-derived melanogenic cytokine (Imokawa et al, 1996b) . GRO-a has been found to be associated with allergy-induced hyperpigmentation when it is secreted by epidermal cells in the elicitation phase, after which it stimulates adjacent melanocytes, leading to hyperpigmentation (Imokawa et al, 1998a) . ET-1 has also been involved in the mechanism of hyperpigmentation in the epidermis of lentigo senilis (Kadono et al, 2001 ) and seborrheic keratosis (Teraki et al, 1996) . As for cytokines or growth factors other than ET that are involved with hyperpigmentation, bFGF (Halaban et al, 1988) or amelanocyte-stimulating hormone (a-MSH) (Chakraborty et al, 1996) are also believed to be involved in UVB-induced pigmentation because they can stimulate the proliferation and/or melanogenesis of cultured human melanocytes and because UVB irradiation causes keratinocytes to produce bFGF (Halaban et al, 1988) or to release a-MSH into the medium (Schauer et al, 1994; Chakraborty et al, 1996) . Whether bFGF or a-MSH is a constitutive mitogen or melanogen for human melanocytes in UVB-induced pigmentation, however, remains to be further clari®ed because of the lack of a secretory form of the former produced by human keratinocytes and the weak mitogenic effect of the latter (Abdel-Malek et al, 1995) . In addition, there is no evidence that antibodies to a-MSH can abrogate the stimulation of proliferation and melanization in cultured human melanocytes elicited by conditioned medium obtained from UVB-exposed keratinocytes. Further, the requirements of other growth factors such as bFGF (Abdel-Malek et al, 1995) or c-AMP raising factors (Halaban et al, 1988) for the stimulation of melanocytes by a-MSH or bFGF, respectively, minimizes their paracrine role in UVBinduced pigmentation. Although intrinsic cytokines associated with stimulation of melanogenesis in various pigmentary disorders have not been fully identi®ed, available evidence reveals that paracrine cytokines interacting between epidermal melanocytes and nonmelanocytic cells in the skin play a central role in epidermal hyperpigmentation. The characteristic features of DF, including ®broblastic tumors in the dermis and hyperpigmentation in the overlying epidermis, allow us to speculate that paracrine cytokines produced by highly proliferative ®broblast-like cells in the dermis might be primarily responsible for the melanogenic stimulation of melanocytes in the epidermis. In this connection, we have already found that conditioned culture medium from proliferating human ®broblasts has a potent ability to stimulate the proliferation of human melanocytes in culture (Imokawa et al, 1996a; 1998b) . Those stimulatory activities were associated with SCF and HGF, which are exclusively secreted in abundance by human ®broblasts derived from aged persons.
Although there is little evidence for their paracrine role among skin cells, SCF and HGF have also been implicated as mitogens for human melanocytes in vitro and in vivo (Matsumoto et al, 1991; Grichnik et al, 1995; Imokawa et al, 1996a Imokawa et al, , 2000 . Treatment with HGF at a concentration of 10 nM has been reported to stimulate the proliferation of cultured human melanocytes (Matsumoto et al, 1991) . Using an in vivo injection protocol, Grichnik et al (1995) and Costa et al (1996) demonstrated a potent capacity of SCF to induce hyperpigmentation in the epidermis, which was accompanied by an increased proliferation of epidermal melanocytes. Consistent with its stimulatory potential, as SCF is also known as mast cell growth factor, increases in the numbers of mast cells and their degranulation were also observed concomitant with melanocyte activation. Thus, based upon the available evidence on the stimulatory effects of several skin-cell-derived cytokines or chemokines on human melanocytes, it is most likely that SCF or HGF derived from the ®broblastic tumors is responsible for the stimulation of epidermal melanocytes, which leads to the hyperpigmentation restricted to the epidermis overlying the ®broblastic tumors in DF. There are different explanations, however, about the nature of the proliferating cells in the DF dermis as to whether the tumor cells are derived from ®broblasts, histiocytes, or dermal dendrocytes (Heenan, 1997) .
This study demonstrates that, despite the lack of a signi®cant difference in the expression of SCF and HGF transcripts in lesional and nonlesional DF epidermis, there is an increased expression of these transcripts in the lesional DF dermis relative to the nonlesional dermis. In contrast, transcripts of other melanogenic cytokines, such as GRO-a, bFGF, and ET-1, are expressed similarly in lesional and nonlesional DF dermis and epidermis. Because the gene expression is essentially expressed per cell (as standardized by GAPDH), the increased expressions of SCF and HGF transcripts imply that cells of the ®broblastic DF tumors produce more of these proteins than do ®broblasts in the nonlesional dermis. In support of this, immunostaining with SCF or HGF antibodies in ®broblasts of the nonlesional DF dermis was substantially negative, indicating that nonproliferating normal ®broblasts produce insigni®cant amounts of SCF or HGF. Based upon this assumption, it is conceivable that there are copious amounts of SCF and HGF secreted throughout the lesional DF dermis, being suf®cient to reach and activate melanocytes in the overlying epidermis. In contrast, the other melanogenic cytokines tested (including GRO-a, bFGF, and ET-1) might also be secreted by ®broblastic tumors, but at concentrations insuf®cient to contact and activate melanocytes. The protein expression of SCF and HGF, as evidenced by immunohistochemistry, is markedly elevated in the lesional DF dermis compared with the nonlesional dermis, whereas for the other melanogenic cytokines tested the transcripts and protein levels of GRO-a, bFGF, and ET-1 are expressed at similar levels between the lesional and nonlesional DF dermis and epidermis. Taken together, our evidence suggests that, in the lesional DF dermis, SCF and HGF are selectively produced and secreted by ®broblastic tumors at concentrations suf®cient to activate melanocytes located in the adjacent epidermis, which results in the hyperpigmentation of the overlying skin. Although there may be other possible explanations as to how melanocytes in the overlying epidermis are activated in DF, the ligand speci®city against different types of cells would help in understanding the results of this study. Thus the fact that, in addition to the increased numbers of activated melanocytes in the overlying epidermis, the number of mast cells located beneath the epidermis is increased 5-fold over that in the nonlesional skin supports the suggestion that at least SCF is secreted in a soluble and diffusible form by ®broblastic tumors at concentrations capable of directly in¯uencing mast cells to increase their number. This strongly suggests that at least soluble SCF plays an important role in the epidermal hyperpigmentation of DF.
A similar type of epidermal hyperpigmentation associated with SCF has been reported in mastocytosis in which the abnormal and excessive conversion of the membrane-bound to the soluble form of SCF in the epidermis plays an essential role in stimulating epidermal melanocytes and proliferating dermal mast cells, respectively (Longley et al, 1993) . Thus, it is conceivable that the threshold concentrations of SCF needed to stimulate melanocytes and mast cells are similar. If mast cells are activated beneath the epidermis by SCF, it seems reasonable to assume that melanocytes are also activated by the same SCF as SCF is also known as mast cell growth factor. Our ®nding that the numbers of mast cells are increased 5-fold in DF skin compared with nonlesional skin may be an interesting indication that the stimulated status of epidermal melanocytes in DF can be ascribed to the action of SCF, which is largely secreted as a soluble isoform by ®broblastic tumors but not by lesional epidermal cells, as supported by the signi®cant increase in SCF gene and protein expression in the lesional dermis but not in the lesional epidermis compared with each nonlesional control. This is concluded because of the existence of soluble SCF, which is released into the medium by cultured human ®broblasts at a level detectable by enzyme-linked immunosorbent assay, but not by cultured human keratinocytes (Imokawa, 1996) , and which diffuses to the nearby epidermis. Thus, it is unlikely that the expression of soluble SCF in the lesional epidermis is stimulated by unknown factors derived from ®broblastic tumor, which results in the stimulation of melanocytes and mast cells as seen for mastocytosis. Unfortunately, as HGF is known just as a stimulator for hepatocytes and melanocytes (Matsumoto et al, 1991) and as there are no other types of skin cells that are known to respond to HGF, it is dif®cult to de®ne the role of HGF in the hyperpigmentation seen in DF. The high expression of HGF in the dermis at both the gene and the protein levels, however, would support a distinct role for HGF in stimulating epidermal melanocytes in DF.
In conclusion, when taken together, the above ®ndings support the pathogenic mechanism of DF in which the proliferating ®broblast-like cells have a potent ability to secrete SCF and HGF, which then diffuse toward the epidermis. This would result in the stimulation of melanocytes located at the basal layer of the epidermis, which would lead in turn to hyperpigmentation limited to the overlying epidermis, presumably accompanied by a concomitant accumulation of mast cells.
